SCHEMBL29566894

SCHEMBL29566894

Cc1ccccc1-c1nc(NS(=O)(=O)c2cnn(C)c2)nc(Oc2ccc(C3CCN(C)CC3)c(F)c2)c1C(F)(F)C(F)(F)F

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SCN9A Q15858 3/20 0.36
▸ JAK2 O60674 3/20 0.36
▸ HTR6 P50406 1/20 0.33
▸ ACVR1 Q04771 1/20 0.33
▸ PCK1 P35558 1/20 0.32
▸ HTR1A P08908 5/20 0.32
▸ HTR7 P34969 5/20 0.32
▸ SLC8A1 P32418 1/20 0.32
▸ KDR P35968 1/20 0.31
▸ GHSR Q92847 1/20 0.31
▸ PIK3CD O00329 1/20 0.31
▸ CSF1R P07333 1/20 0.31
▸ CDK4 P11802 1/20 0.31
▸ CDK6 Q00534 1/20 0.31
▸ EGFR P00533 1/20 0.31
▸ INSR P06213 1/20 0.31
▸ MET P08581 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24310541 1.00 SCN9A (0.36) SCN9AJAK2HTR6ACVR1PCK1
SCHEMBL24309558 0.95 SCN9A (0.34) SCN9AJAK2HTR6PCK1HTR1A
SCHEMBL29566773 0.95 SCN9A (0.34) SCN9AJAK2HTR6PCK1HTR1A
SCHEMBL29567070 0.91 SCN9A (0.40) SCN9AJAK2HTR1AHTR7SLC8A1
SCHEMBL24310783 0.91 SCN9A (0.40) SCN9AJAK2HTR1AHTR7SLC8A1
SCHEMBL24309541 0.90 HTR1A (0.34) SCN9AJAK2HTR6PCK1HTR1A
SCHEMBL29566869 0.89 HTR1A (0.36) SCN9AJAK2HTR6PCK1HTR1A
SCHEMBL24310107 0.89 HTR1A (0.36) SCN9AJAK2HTR6PCK1HTR1A
SCHEMBL24309520 0.88 SCN9A (0.35) SCN9AJAK2PCK1HTR1AHTR7
SCHEMBL29566590 0.88 SCN9A (0.35) SCN9AJAK2PCK1HTR1AHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4225748-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2023-08-16 — — EP disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed
Send feedback